PTK787对K562细胞增殖及细胞周期作用的影响(3)
第1页 |
参见附件。
[5] Lin B,Podar K,Gupta D,et al.The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myelom a cells in the bone marrow microenvironment[J].Cancer Res,2002,62(17):5019-5026.
[6] Roboz G J,Giles F J,List A F,et al.Phase l study of PTK787/ZK 222584.a small molecule tyrosine kinase receptor inhibitor,for the treatment of acute myeloid leukemia and myeloid ys plastic syndrome[J].Leukemia,2006,20(6):952-957.
[7]茆勇军,李海泓,李剑峰,等.蛋白酪氨酸激酶信号转导途径与抗肿瘤药物[J].药学学报,2008,43(4):323,334.
[8] Bold G, Buchdtmger E.PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases,impai vascular endothelial growth factor-induced responses and tumor growth after oral administration[J].Cancer Res,2000,60(8):2178-2189.
[9] Le Coutre P, Ottmann O G, Giles F.Nilotinib formerly AMN107, a highly selective BCR-ABL tyrosine kinase inhibitor,is active in patients with imatinib resistant or intolerant accelerated-phase chronic myelogenous leukemia[J].Blood,2008,1114(1):1834-1839.
[10] Liu Y,Poon R T,Li Q,et a1.Both antiangiogenesis and angiogenesis independent effects are responsible for hepatocellular carcinoma growth, arrest by tyrosine kinase inhibitor K787/ZK222584[J].Cancer Res,2005,65(9):3691-3699.
[11] Zhao J,Pestell R,Guan J L.Transcriptional activation cyclin D1 promoter by FAK contributes to cell cycle progression[J].Mol Biol Cell,2001,12(1):4066-4077.
(收稿日期:2013-03-06) (本文编辑:连胜利)
您现在查看是摘要介绍页,详见PDF附件。